Results 31 to 40 of about 2,769,024 (292)

Safety, immunogenicity and duration of protection of a candidate malaria vaccine in Mozambique / Seguridad, inmunogenicidad y duración de protección del candidato a vacuna contra la malaria en Mozambique [PDF]

, 2011
Malaria, caused by Plasmodium falciparum parasites remains a huge public health problem and a major cause of morbidity and mortality in sub-Saharan Africa, especially among children and infants.
Aide, Pedro Carlos Paulino
core   +7 more sources

Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants. [PDF]

, 2008
BACKGROUND: The RTS,S/AS malaria vaccine is being developed for delivery through the World Health Organization's Expanded Program on Immunization (EPI).
Machera, Francisca, Membi, Christopher, Kubhoja, Sulende, Cohen, Joe, Abdulla, Salim, Aebi, Thomas, Oberholzer, Rolf, Omari, Said, Ballou, W Ripley, Jumanne, Ajuza, Schellenberg, David M, Dubois, Marie-Claude, Salim, Nahya, Lievens, Marc, Carter, Terrell, Shomari, Mwanjaa, Urassa, Alwisa, Juma, Omar, Leach, Amanda, Demoitié, Marie-Ange, Vekemans, Johan, Mshinda, Hassan, Villafana, Tonya, Tanner, Marcel   +23 more
core   +1 more source

Psychiatric adverse events associated with the COVID-19 vaccines approved in the Republic of Korea: a systematic review [PDF]

Osong Public Health and Research Perspectives
This systematic review evaluated psychiatric adverse events (AEs) following vaccination against coronavirus disease 2019 (COVID-19). We included studies that reported or investigated psychiatric AEs in individuals who had received an approved COVID-19 ...
Seungeun Ryoo, Miyoung Choi, Nam-Kyong Choi, Hyoung-Shik Shin, Jun Hee Woo, Byung-Joo Park, Sanghoon Oh   +6 more
doaj   +1 more source

Calibrated comparison of SARS-CoV-2 neutralizing antibody levels in response to protein-, mRNA-, and vector-based COVID-19 vaccines

npj Vaccines, 2022
SARS-CoV-2 neutralizing antibodies have been suggested to reflect the efficacy of COVID-19 vaccines. This study reports the direct comparison of the SARS-CoV-2 neutralizing antibody response elicited by a protein- (NVX-CoV2373), an mRNA- (Comirnaty), and
Michael Karbiener, Maria R. Farcet, Andreas Zollner, Taisei Masuda, Mitsuhiro Mori, Alexander R. Moschen, Thomas R. Kreil   +6 more
doaj   +1 more source

The safety of vaccines

Drug Discovery Today, 2004
Vaccines have had a considerable impact on society by eliminating the threat from several infectious diseases. Although vaccines have generally proven to be safe, safety issues have arisen that have resulted in some members of the public having a poor perception of vaccines.
O'Hagan, Derek T., Rappuoli, Rino
openaire   +2 more sources

COVID-19 vaccine safety

Revista Peruana de Medicina Experimental y Salud Pública, 2021
The development and production of safe and effective vaccines against coronavirus disease 2019 (COVID-19) provides hope for controlling the current pandemic.
Nataniel Aldo Chaparro Mérida, Dayany Moreno Samper, Alex Omar Franco Lacato   +2 more
doaj   +1 more source

Satisfactory safety and immunogenicity of MSP3 malaria vaccine candidate in Tanzanian children aged 12-24 months. [PDF]

, 2009
BACKGROUND: Development and deployment of an effective malaria vaccine would complement existing malaria control measures. A blood stage malaria vaccine candidate, Merozoite Surface Protein-3 (MSP3), produced as a long synthetic peptide, has been shown ...
Gesase Samwel, Druilhe, Pierre, Chilengi Roma, Roma Chilengi, Method D Segeja, Seth, Misago, Msham Salum, Francis Filbert, Lemnge, Martha, Samwel Sembuche, Salum Msham, Noor Ramadhani, Cousens Simon, Sembuche, Samwel, Minja Daniel, Martha Lemnge, Simon Cousens, Samuel Bosomprah, Chilengi, Roma, Samwel Gesase, Lusingu, John PA, Gesase, Samwel, John PA Lusingu, Rutta, Acleus, Bosomprah Samuel, Cousens, Simon, Ramadhani Noor, Acleus Rutta, Pierre Druilhe, Seth Misago, Segeja Method D, Minja, Daniel, Msham, Salum, Druilhe Pierre, Daniel Minja, Francis, Filbert, Noor, Ramadhani, Lemnge Martha, Bosomprah, Samuel, Lusingu John PA, Rutta Acleus, Misago Seth, Segeja, Method D, Sembuche Samwel, Filbert Francis   +44 more
core   +1 more source

Pre-Clinical Safety and Immunogenicity Study of a Coronavirus Protein-Based Subunit Vaccine for COVID-19

, 2023
Creating an effective and safe vaccine is critical to fighting the coronavirus infection successfully. Several types of COVID-19 vaccines exist, including inactivated, live attenuated, recombinant, synthetic peptide, virus-like particle-based, DNA and ...
Aziz Nakhanov, Sergazy Nurabayev, Lespek Kutumbetov, Aibol Terebay, Kuanysh Jekebekov, Ainur Nurpeisova, Zhandos Abay, Markhabat Kassenov, Aslan Kerimbayev, Nurika Assanzhanova, Olga Chervyakova, Syrym Kopeyev, Gulnur Nakhanova, Elina Kalimolda, Sabina Moldagulova, Sandugash Sadikaliyeva, Kamshat Shorayeva, Aisha Issabek, Kunsulu Zakarya, Ali Tulendibayev, Yergali Abduraimov, Mukhit Orynbayev, Zharkinay Absatova   +22 more
core   +1 more source

Safety of Vaccination within First Year of Life—The Experience of One General Medicine Center

Children, 2023
Vaccines represent an important preventive strategy in paediatric populations, but the rate of vaccination has been constantly declining in the last decade.
Claudia Felicia Pop, Petronela Coblisan, Ligia Capalna, Paraschiva Cherecheș Panța, Anca Dana Buzoianu, Ioana Corina Bocsan   +5 more
doaj   +1 more source

Vaccine safety in Australia during the COVID-19 pandemic: Lessons learned on the frontline

Frontiers in Public Health, 2022
Surveillance of Adverse Events Following Vaccination in the Community (SAEFVIC), Victoria's vaccine safety service for reporting adverse events following immunisation (AEFI), has provided integrated spontaneous surveillance and clinical services for ...
Ingrid Laemmle-Ruff, Georgina Lewis, Hazel J. Clothier, Hazel J. Clothier, Hazel J. Clothier, Gerardo Luis Dimaguila, Gerardo Luis Dimaguila, Michelle Wolthuizen, Jim Buttery, Jim Buttery, Jim Buttery, Jim Buttery, Nigel W. Crawford, Nigel W. Crawford, Nigel W. Crawford   +14 more
doaj   +1 more source